Biotechnology

Alnylam Pharmaceuticals

$169.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.28 (-0.75%) As of 4:01 PM UTC today

Why Robinhood?

You can buy or sell ALNY and other stocks, options, and ETFs commission-free!

About ALNY

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. The listed name for ALNY is Alnylam Pharmaceuticals, Inc. Common Stock.

CEO
John M. Maraganore
Employees
1,323
Headquarters
Cambridge, Massachusetts
Founded
2002
Market Cap
19.50B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.21M
High Today
$172.54
Low Today
$169.00
Open Price
$172.54
Volume
90.86K
52 Week High
$175.41
52 Week Low
$84.97

Collections

ALNY Earnings

-$2.23
-$1.49
-$0.74
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 4, Pre-Market

You May Also Like

BNOV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure